Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02511990 · ClinicalTrials.gov registry record · Phase 1
A Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 10-1074
A Phase 1 study of Healthy and HIV, sponsored by Rockefeller University.
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
- 2
- Study locations
NCT02511990: Completed Phase 1 study of Healthy and HIV, sponsored by Rockefeller University.
NCT02511990 is a Phase 1 study of Healthy and HIV that has completed, run by Rockefeller University. The registered enrollment target is 33 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (95% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02511990, a Phase 1 study of Healthy and HIV, has completed, sponsored by Rockefeller University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a phase 1 clinical trial to evaluate the safety, pharmacokinetics and the antiretroviral effects of the highly neutralizing anti-HIV-1 monoclonal antibody 10-1074 in HIV-infected and HIV-uninfected individuals.
Interventions
- BIOLOGICAL 3 mg/kg, single dose IV administration of 10-1074
- BIOLOGICAL 10 mg/kg, single dose IV administration of 10-1074
- BIOLOGICAL 30 mg/kg, single dose IV administration of 10-1074
Study Locations (2)
New York
- The Rockefeller University - New York
Other
- University of Cologne - Cologne
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2015-07 |
| Est. Completion | 2017-12 |
| Phase | Phase 1 |
What the finished NCT02511990 record still lists
NCT02511990 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (95% lower).
The record links to 2 conditions, with Healthy appearing as the primary indexed condition, and to 3 interventions - of which 3 mg/kg, single dose IV administration of 10-1074 is the first listed.
NCT02511990 reports a single indexed study location in New York, Other.
Frequently Asked Questions
What is clinical trial NCT02511990 about?
NCT02511990 is a clinical study titled "A Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 10-1074". This is a phase 1 clinical trial to evaluate the safety, pharmacokinetics and the antiretroviral effects of the highly neutralizing anti-HIV-1 monoclonal antibody 10-1074 in HIV-infected and HIV-uninfected individuals.
What is the current status of trial NCT02511990?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2015-07. Estimated completion is 2017-12.
What conditions does trial NCT02511990 study?
This clinical trial studies the following conditions: Healthy, HIV.
What interventions are being tested in trial NCT02511990?
The interventions under investigation include: 3 mg/kg, single dose IV administration of 10-1074 (BIOLOGICAL), 10 mg/kg, single dose IV administration of 10-1074 (BIOLOGICAL), 30 mg/kg, single dose IV administration of 10-1074 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02511990?
This trial is sponsored by Rockefeller University, which has 117 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02511990 being conducted?
This trial has 2 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02511990's enrollment target sits among peer trials
33 641st of 1090 higher than 445 of 1,090 other Healthy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
A Study of LY3867070 in Healthy Participants
RECRUITING · Phase 1
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants.
RECRUITING · Phase 1
-
Evaluate the Pharmacokinetics, Safety, and Tolerability of NSHO-101 in Healthy Participants
RECRUITING · Phase 1
-
Comparison of the Short-Term Effect of Dietary Carbohydrate Restriction Versus Exogenous Ketone Supplementation on Myocardial Glucose Suppression and Timing to Achieve a State of Ketosis Using FDG PET/CT Serial Imaging
RECRUITING · Phase 1
-
A Study of V118E in Healthy Participants (V118E-003)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia